Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Who will be eligible? An investigation of the dementia population eligible for cholinesterase treatment following the change in NICE guidance.

Authors
  • Matthews, Fiona E
  • Muniz-Terrera, Graciela
  • McKeith, Ian
  • Brayne, Carol
Type
Published Article
Journal
International journal of geriatric psychiatry
Publication Date
Jul 01, 2010
Volume
25
Issue
7
Pages
719–724
Identifiers
DOI: 10.1002/gps.2413
PMID: 19946863
Source
Medline
License
Unknown

Abstract

The population impact of new NICE criteria of excluding high MMSE scores is to exclude one in five individuals with AD and a further one in ten of those with a mixed disease. Changing the guidance has almost balanced the loss of treatment for the high MMSE group (13%) with the introduction of treatment for those scoring 10/11 (11%).

Report this publication

Statistics

Seen <100 times